Genentech: News Features

<!doctype html> <html lang="en-us" > <head> <meta charset="utf-8"> <title>Genentech: News Features</title> <meta name="description" content="Access media kits and related information for our featured news stories."> <link href="https://feeds.feedburner.com/Genentech-Stories" rel="alternate" type="application/rss+xml" title="Genentech - Read about breakthrough science, the everyday people who make it happen, and the patients we serve." /> <meta name="viewport" content="width=device-width, initial-scale=1"> <meta property="og:title" content="Genentech: News Features" /> <meta property="og:description" content="Access media kits and related information for our featured news stories." /> <meta property="og:image" content="https://www.gene.com/assets/frontend/img/social.png" /> <meta name="twitter:card" content="summary_large_image"> <meta name="twitter:site" content="@genentech"> <meta name="twitter:title" content="Genentech: News Features"> <meta name="twitter:description" content="Access media kits and related information for our featured news stories."> <meta name="twitter:creator" content="@genentech"> <meta name="twitter:image:src" content="https://www.gene.com/assets/frontend/img/social.png"> <meta name="csrf-token" content=""> <script data-icons="/assets/frontend/svg/icons.svg"></script> <link rel="preload" as="style" href="https://www.gene.com/build/assets/v3-main-site-BHL2dwv-.css" /><link rel="stylesheet" href="https://www.gene.com/build/assets/v3-main-site-BHL2dwv-.css" /> <link rel="icon" href="/assets/frontend/img/favicon.ico"> <link rel="apple-touch-icon-precomposed" href="/assets/frontend/img/apple-icon-touch.png"> <link rel="sitemap" type="application/xml" title="Sitemap" href="/sitemap" /> <link rel="stylesheet" href="https://www.gene.com/assets/frontend/css/custom/galaxySearch.css" /> <link rel="canonical" href="https://www.gene.com/media/news-features"> <style> .fit-vids-style { display: none; } </style> <script> var jQ = { queue: [], ready: function (f) { if (typeof f=='function') jQ.queue.push(f); return jQ; }, unq: function () { for (var i = 0; i < jQ.queue.length; i++) jQ.queue[i](); jQ.queue = null; } }; if (typeof window.jQuery == 'undefined') { window.jQuery = window.$ = jQ.ready; } var Gene = { universal: {}, configs: {}, main: {}, features: {}, custom: {}, analytics: {} }; Gene.configs.paths = { prepend : '/' } </script>  <script src="https://cdn.cookielaw.org/scripttemplates/otSDKStub.js" data-document-language="true" type="text/javascript" charset="UTF-8" data-domain-script="0fd064ad-a247-479a-9e43-5ca8b40bcb43" ></script> <script type="text/javascript"> function OptanonWrapper() { } </script>  <script> var isReturningUser = false; if (window.localStorage) { isReturningUser = localStorage.getItem('RETURNING_USER') != null; localStorage.setItem('RETURNING_USER', true); } var referrer = 'direct'; if (document.referrer && document.referrer != "") { referrer = document.referrer; } var dataLayer = [{ 'userType': isReturningUser ? 'returning' : 'new', 'referrer': referrer, 'contentID': 'node-8a04f4f1-594b-4d45-9301-95001db6e32b', 'contentID': 'node-8a04f4f1-594b-4d45-9301-95001db6e32b', }]; </script> <link rel="modulepreload" href="https://www.gene.com/build/assets/analytics-standalone-YYY1jLtB.js" /><script src="https://www.gene.com/build/assets/analytics-standalone-YYY1jLtB.js"></script> <script type="text/javascript"> function getQueryParam(str) { var v = window.location.search.match(new RegExp('(?:[\?\&]'+str+'=)([^&]+)')); return v ? v[1] : null; } var src = getQueryParam('src'); if (src) { Gene.analytics.setSource('Source', src); } </script> <script src="https://cdn.jsdelivr.net/gh/alpinejs/alpine@v2.x.x/dist/alpine.min.js" defer></script> </head> <body class=" ">  <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-PPKDWPC');</script>   <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-PPKDWPC" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>  <header id='gene-header' class='header'></header> <div class="l-page-overlay"></div> <script> // @todo: This is temporary code - to be moved to separate file (both css & js). var relatedTranslations = []; var currentLangId = 'en'; var langSwitchLabels = {};; $(document).ready(function () { if (relatedTranslations.length > 0) { var selector = $('<select data-minimum-results-for-search="50" data-width="resolve" style="margin-top: -15px; width: 160px;"></select>'); selector.append($('<option>' + (langSwitchLabels[currentLangId] ?? currentLangId) + '</option>')); relatedTranslations.forEach(function (translation) { selector.append($('<option value="' + translation.calculated_path + '">' + (langSwitchLabels[translation.lang_id] ?? translation.lang_id) + '</option>')); }); selector.on('change', function () { if ($(this).val().length > 0) { window.location = '/switch?request_path=' + $(this).val(); } }); var breadcrumbs = $('.js-nav-container .breadcrumbs').first(); if (breadcrumbs) { var container = $('<div class="lang-switch-container" style="display: flex; flex-direction: row; justify-content: space-between; align-content: flex-start;"></div>'); container.append(breadcrumbs.clone()); container.append(selector); breadcrumbs.hide(); breadcrumbs.after(container); } } }); </script> <style> .lang-switch-container { margin-bottom: 10px; } .lang-switch-container .select2-container { position: relative; top: -13px; } .lang-switch-container .select2-container .select2-selection--single { margin-top: 0px; } .lang-switch-container .select2-container--default .select2-selection--single .select2-selection__arrow { top: -10px; } </style> <div class="ie-warning" style="display:none;"> <div class="ie-warning__container constrained"> <h2 class="ie-warning__text">Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.</h2> </div> </div>  <div class="header__spacer "></div> <div class="js-nav-container "> <script type="text/javascript"> Gene.analytics.setAudience('media'); </script> <script> $(function(){ // Init custom configs Gene.custom.configs = Gene.custom.configs || {}; // define custom setup Gene.custom.configs.datatables = { "bSort": false, "aoColumnDefs": [ { // Content searchable "bSearchable": true, "aTargets": [ 0 ] } ], "fnInitComplete": function(){ Gene.features.select2.init(); $('.dataTable').removeClass('hide-until-initialized'); // Stickem plugin depends on this event; get new window height. $(window).trigger('resize'); }, "fnDrawCallback": function() { var length = $('.dataTable').DataTable().page.info().recordsDisplay; $('.js-results-count').html(length + ' result' + (length !== 1 ? 's' : '')); }, "oLanguage": { "sSearch": '', "sSearchPlaceholder": 'Find News Features', "sLengthMenu": '<select>'+ '<option value="10">SHOW 10</option>'+ '<option value="20">SHOW 20</option>'+ '<option value="30">SHOW 30</option>'+ '<option value="40">SHOW 40</option>'+ '<option value="50">SHOW 50</option>'+ '<option value="-1">SHOW All</option>'+ '</select>', "oPaginate": { "sPrevious": '<svg><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-chevron-left"></use></svg>', "sNext": '<svg><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-chevron-right"></use></svg>' } } }; }); </script> <div class="constrained"> <div style="position: absolute; width: 260px; height: 100%;"> <div class="l-rail-left"> <div class="nav-secondary-container"> <nav class="nav-secondary js-nav-secondary"> <div class="nav-secondary__header "> <a class="nav-secondary__link" href="/media">Media</a> </div> <ul class="nav-secondary__children"> <li class="nav-secondary__child current"> <a class="nav-secondary__link" href="/media/news-features">News Features</a> </li> <li class="nav-secondary__child "> <a class="nav-secondary__link" href="/media/press-releases">Press Releases</a> </li> <li class="nav-secondary__child "> <a class="nav-secondary__link" href="/media/statements">Statements</a> </li> <li class="nav-secondary__child "> <a class="nav-secondary__link" href="/media/company-information">Company Information</a> </li> <li class="nav-secondary__child "> <a class="nav-secondary__link" href="/media/news-alerts">Sign Up For News Alerts</a> </li> </ul> </nav> <aside class="nav-secondary__media-inquiries"> <div class="nav-secondary__media-inquiries-header">Media Inquiries</div> <a id="start-new-submission" class="button" href="/contact-us/submit-media-inquiry"> Email Us <svg class="icon nav-secondary__button-icon"><use xlink:href="#icon-share-email"></use></svg> </a> </aside> </div> </div> </div> </div> <div class="constrained"> <div class="l-grid"> <div class="l-content-container"> <div class="l-content"> <div class="breadcrumbs"> <a href="/media">Media</a> / <a href="/media/news-features">News Features</a> </div> <div class="block-basic"> <h1>News Features</h1> <p class="intro">Access media kits and related information for our featured news stories.</p> </div> <p class="form-pagination__result-count js-results-count">65 results</p> <table class="display dataTable media-list hide-until-initialized" id="news-features"> <thead> <tr> <th></th> </tr> </thead> <tbody> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/fda-approves-new-targeted-treatment-for-advanced-hormone-receptor-positive-her2-negative-breast-cancer-with-a-pik3ca-mutation"> <img src="/assets/content/news_feature_thumbnail/News-Feature-Thumbnail-Image.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">10 Oct 2024</p> <a class="media-list-feature__title" href="/media/news-features/fda-approves-new-targeted-treatment-for-advanced-hormone-receptor-positive-her2-negative-breast-cancer-with-a-pik3ca-mutation"> FDA Approves New Targeted Treatment For Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With A PIK3CA Mutation </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/itovebi"> Itovebi </a> <p class="media-list-feature__excerpt">On October 10, 2024, the FDA approved Genentech鈥檚 medicine for PIK3CA-mutated HR+, HER- advanced breast cancer.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-new-targeted-treatment-for-advanced-hr-positive-her2-negative-breast-cancer-with-a-pik3camutation/Itovebi_Media_Kit_2024-10.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/fda-approves-first-and-only-twice-a-year-10-minute-subcutaneous-injection-for-people-with-relapsing-and-progressive-multiple-sclerosis"> <img src="/assets/content/news_feature_thumbnail/1235_Ocrevus+Zunovo+Approval_Thumbnail_340x340.png" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">13 Sep 2024</p> <a class="media-list-feature__title" href="/media/news-features/fda-approves-first-and-only-twice-a-year-10-minute-subcutaneous-injection-for-people-with-relapsing-and-progressive-multiple-sclerosis"> FDA Approves the First and Only Twice-A-Year 10-Minute Subcutaneous Injection for People with Relapsing and Progressive Multiple Sclerosis </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/ocrevus-zunovo"> Ocrevus Zunovo </a> <p class="media-list-feature__excerpt">On September 13, 2024, the FDA approved Genentech鈥檚 subcutaneous medicine for both relapsing and progressive multiple sclerosis in adults.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-first-and-only-twice-a-year-10-minute-subcutaneous-injection-for-people-with-relapsing-and-progressive-multiple-sclerosis/genentech_ocrevus_zunovo_2024-09-13_media_kit.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/fda-approves-the-first-and-only-medicine-for-children-and-adults-with-one-or-more-food-allergies"> <img src="/assets/content/news_feature_thumbnail/Xolair_FA_NF_Thumb_340x340_r1v1.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">16 Feb 2024</p> <a class="media-list-feature__title" href="/media/news-features/fda-approves-the-first-and-only-medicine-for-children-and-adults-with-one-or-more-food-allergies"> FDA APPROVES THE FIRST AND ONLY MEDICINE FOR CHILDREN AND ADULTS WITH ONE OR MORE FOOD ALLERGIES </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/xolair"> Xolair </a> <p class="media-list-feature__excerpt">On February 16, 2024, the FDA approved the first and only medicine to reduce allergic reactions in people with one or more IgE-mediated food allergies.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-the-first-and-only-medicine-for-children-and-adults-with-one-or-more-food-allergies/genentech_xolair_2024-02-16_media_kit.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/fda-approves-genentechs-fixed-duration-bispecific-antibody-for-relapsed-refractory-diffuse-large-b-cell-lymphoma"> <img src="/assets/content/news_feature_thumbnail/1188_Columvi+Approval_340x340.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">15 Jun 2023</p> <a class="media-list-feature__title" href="/media/news-features/fda-approves-genentechs-fixed-duration-bispecific-antibody-for-relapsed-refractory-diffuse-large-b-cell-lymphoma"> FDA Approves Genentech鈥檚 Fixed-Duration Bispecific Antibody for Relapsed/Refractory Diffuse Large B-Cell Lymphoma </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/columvi"> Columvi </a> <p class="media-list-feature__excerpt">On June 15, 2023, the FDA approved Genentech鈥檚 medicine for relapsed and refractory diffuse large B-cell lymphoma.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-genentechs-fixed-duration-bispecific-antibody-for-relapsed-refractory-diffuse-large-b-cell-lymphoma/genentech_columvi_2023-06-15_media_kit.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/fda-approves-genentech-medicine-for-people-with-previously-untreated-diffuse-large-b-cell-lymphoma"> <img src="/assets/content/news_feature_thumbnail/1181_Polivy-1L-Approval_Hero_Media_340x340.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">19 Apr 2023</p> <a class="media-list-feature__title" href="/media/news-features/fda-approves-genentech-medicine-for-people-with-previously-untreated-diffuse-large-b-cell-lymphoma"> FDA Approves Genentech鈥檚 Medicine For People With Certain Types of Previously Untreated Diffuse Large B-Cell Lymphoma </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/polivy"> Polivy </a> <p class="media-list-feature__excerpt">On April 19, 2023, the FDA approved Genentech鈥檚 medicine for certain types of previously untreated DLBCL.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-genentech-medicine-for-people-with-previously-untreated-diffuse-large-b-cell-lymphoma/genentech_polivy_2023-04-19_media_kit.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/fda-approves-genentechs-first-in-class-medicine-for-relapsed-refractory-follicular-lymphoma-after-at-least-two-prior-therapies"> <img src="/assets/content/news_feature_thumbnail/1172_Lunsumio-Approval_Header_Hero_Media_340x340.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">22 Dec 2022</p> <a class="media-list-feature__title" href="/media/news-features/fda-approves-genentechs-first-in-class-medicine-for-relapsed-refractory-follicular-lymphoma-after-at-least-two-prior-therapies"> FDA Approves Genentech鈥檚 First-in-Class Medicine for Relapsed/Refractory Follicular Lymphoma After at Least Two Prior Therapies </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/lunsumio"> Lunsumio </a> <p class="media-list-feature__excerpt">On December 22, 2022, the FDA approved Genentech鈥檚 medicine for advanced follicular lymphoma.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-genentechs-first-in-class-medicine-for-relapsed-refractory-follicular-lymphoma-after-at-least-two-prior-therapies/genentech_lunsumio_2025-01-15_media_kit.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/fda-approves-genentech-s-bispecific-antibody-for-two-leading-causes-of-vision-loss"> <img src="/assets/content/news_feature_thumbnail/1139_Gene_Ophthalmology_Thumbnail+340x340.png" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">28 Jan 2022</p> <a class="media-list-feature__title" href="/media/news-features/fda-approves-genentech-s-bispecific-antibody-for-two-leading-causes-of-vision-loss"> FDA Approves Genentech鈥檚 Bispecific Antibody For Two Leading Causes Of Vision Loss </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/vabysmo"> Vabysmo </a> <p class="media-list-feature__excerpt">On January 28, 2022, the FDA approved Genentech鈥檚 bispecific antibody for wet age-related macular degeneration (AMD) and diabetic macular edema (DME).</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-genentechs-bispecific-antibody-for-two-leading-causes-of-vision-loss/genentech_vabysmo_2023-04-13_media_kit.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/fda-approves-genentech-s-new-treatment-for-wet-age-related-macular-degeneration-amd"> <img src="/assets/content/news_feature_thumbnail/Gene_Ophthalmology_Thumbnail+340x340.png" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">22 Oct 2021</p> <a class="media-list-feature__title" href="/media/news-features/fda-approves-genentech-s-new-treatment-for-wet-age-related-macular-degeneration-amd"> FDA Approves Genentech鈥檚 New Treatment For Wet Age-Related Macular Degeneration (AMD) </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/susvimo"> Susvimo </a> <p class="media-list-feature__excerpt">On October 22, 2021, the FDA approved Genentech鈥檚 treatment for wet AMD, a leading cause of blindness.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-genentech-s-new-treatment-for-wet-age-related-macular-degeneration-amd/susvimo_2025-02-11_media_kit.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/fda-approves-genentech-s-immunotherapy-for-people-with-certain-types-of-early-stage-lung-cancer"> <img src="/assets/content/news_feature_thumbnail/Tecentriq_Thumbnail_Image_340x340.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">15 Oct 2021</p> <a class="media-list-feature__title" href="/media/news-features/fda-approves-genentech-s-immunotherapy-for-people-with-certain-types-of-early-stage-lung-cancer"> FDA Approves Genentech鈥檚 Immunotherapy For People With Certain Types Of Early-Stage Lung Cancer </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/tecentriq"> Tecentriq </a> <p class="media-list-feature__excerpt">On October 15, 2021, the FDA approved our immunotherapy for adjuvant treatment of certain types of lung cancer</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-genentech-s-immunotherapy-for-people-with-certain-types-of-early-stage-lung-cancer/tecentriq-media-kit-nsclc-2021-10-15.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/fda-grants-full-approval-for-genentech-s-acute-myeloid-leukemia-medicine-under-the-fda-s-real-time-oncology-review-pilot-program-and-project-orbis-initiative"> <img src="/assets/content/news_feature_thumbnail/1098_Venclexta_AML_news_feature_thumbnail_20-10-21_340x340.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">21 Oct 2020</p> <a class="media-list-feature__title" href="/media/news-features/fda-grants-full-approval-for-genentech-s-acute-myeloid-leukemia-medicine-under-the-fda-s-real-time-oncology-review-pilot-program-and-project-orbis-initiative"> FDA Grants Full Approval For Genentech鈥檚 Acute Myeloid Leukemia Medicine Under the FDA鈥檚 Real-Time Oncology Review Pilot Program And Project Orbis Initiative </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/venclexta"> Venclexta </a> <p class="media-list-feature__excerpt">On October 16, 2020, the FDA granted full approval for our acute myeloid leukemia (AML) medicine.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-grants-full-approval-for-genentech-s-acute-myeloid-leukemia-medicine-under-the-fda-s-real-time-oncology-review-pilot-program-and-project-orbis-initiative_v2/venclexta_media_kit_2020-10-21.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/fda-approves-genentech-s-treatment-for-neuromyelitis-optica-spectrum-disorder-nmosd"> <img src="/assets/content/news_feature_thumbnail/News+Feature+Thumbnail+Image_340x340_FINAL.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">14 Aug 2020</p> <a class="media-list-feature__title" href="/media/news-features/fda-approves-genentech-s-treatment-for-neuromyelitis-optica-spectrum-disorder-nmosd"> FDA Approves Genentech鈥檚 Treatment for Neuromyelitis Optica Spectrum Disorder (NMOSD) </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/enspryng"> Enspryng </a> <p class="media-list-feature__excerpt">Learn more about the recent FDA approval of our neuromyelitis optica spectrum disorder (NMOSD) medicine.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-genentech-s-treatment-for-neuromyelitis-optica-spectrum-disorder-nmosd_v2/enspryng_media_kit_2020-08-14_v2.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/fda-approves-genentechs-treatment-for-spinal-muscular-atrophy-SMA-in-adults-and-children-2-months-and-older"> <img src="/assets/content/news_feature_thumbnail/SMA_340x340.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">7 Aug 2020</p> <a class="media-list-feature__title" href="/media/news-features/fda-approves-genentechs-treatment-for-spinal-muscular-atrophy-SMA-in-adults-and-children-2-months-and-older"> FDA Approves Genentech鈥檚 Treatment for Spinal Muscular Atrophy (SMA) in Adults and Children 2 Months and Older </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/evrysdi"> Evrysdi </a> <p class="media-list-feature__excerpt">Learn more about the recent FDA approval of our spinal muscular atrophy (SMA) medicine.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-genentechs-treatment-for-spinal-muscular-atrophy-SMA-in-adults-and-children-2-months-and-older/Evrysdi_Media_Kit_2022-10-05.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/genentech-medicine-received-accelerated-fda-approval-as-a-new-treatment-option-for-people-with-previously-treated-aggressive-lymphoma"> <img src="/assets/content/news_feature_thumbnail/0519_Polivy_News_Feature_340x340.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">10 Jun 2019</p> <a class="media-list-feature__title" href="/media/news-features/genentech-medicine-received-accelerated-fda-approval-as-a-new-treatment-option-for-people-with-previously-treated-aggressive-lymphoma"> Genentech Medicine Received Accelerated FDA Approval as a New Treatment Option for People with Previously Treated Aggressive Lymphoma </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/polivy"> Polivy </a> <p class="media-list-feature__excerpt">On June 10, 2019, the FDA granted accelerated approval for a new Genentech medicine in combination with bendamustine plus Rituxan (rituximab) for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma who have received at least two prior therapies.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/genentech-medicine-received-accelerated-fda-approval-as-a-new-treatment-option-for-people-with-previously-treated-aggressive-lymphoma/polivy_media_kit_2019_06_10.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/fda-approves-new-fixed-duration-treatment-option-for-previously-untreated-chronic-lymphocytic-leukemia"> <img src="/assets/content/news_feature_thumbnail/1063_Venclexta_Murano_Approval_Newafeature_thumbnail_340x340.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">15 May 2019</p> <a class="media-list-feature__title" href="/media/news-features/fda-approves-new-fixed-duration-treatment-option-for-previously-untreated-chronic-lymphocytic-leukemia"> FDA Approves New Fixed-Duration Treatment Option for Previously Untreated Chronic Lymphocytic Leukemia </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/venclexta"> Venclexta </a> <p class="media-list-feature__excerpt">On May 15, 2019, the FDA approved a fixed-duration, chemotherapy-free combination of Genentech medicines for people with previously untreated chronic lymphocytic leukemia.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-new-fixed-duration-treatment-option-for-previously-untreated-chronic-lymphocytic-leukemia/venclexta_media_kit_2019_05_15.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/fda-approves-new-adjuvant-treatment-for-certain-patients-with-her2-positive-early-breast-cancer"> <img src="/assets/content/news_feature_thumbnail/1049_Kadcyla_MOA_340x340.png" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">3 May 2019</p> <a class="media-list-feature__title" href="/media/news-features/fda-approves-new-adjuvant-treatment-for-certain-patients-with-her2-positive-early-breast-cancer"> FDA Approves New Adjuvant Treatment for Certain Patients with HER2-Positive Early Breast Cancer </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/kadcyla"> Kadcyla </a> <p class="media-list-feature__excerpt">On May 3, 2019, the FDA approved a Genentech medicine for adjuvant (after surgery) treatment of people with HER2-positive early breast cancer (EBC) who have residual invasive disease after neoadjuvant (before surgery) taxane and Herceptin-based treatment.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-new-adjuvant-treatment-for-certain-patients-with-her2-positive-early-breast-cancer/Kadcyla_Media_Kit_2019-05-06.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a>  |  <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-new-adjuvant-treatment-for-certain-patients-with-her2-positive-early-breast-cancer/Kadcyla_B-roll_2019-05-06.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download B-Roll</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/fda-approves-first-and-only-cancer-immunotherapy-for-initial-treatment-of-difficult-to-treat-type-of-lung-cancer"> <img src="/assets/content/news_feature_thumbnail/1057_Tecentriq_News_Feature_Media_Thumbnail_340x340.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">18 Mar 2019</p> <a class="media-list-feature__title" href="/media/news-features/fda-approves-first-and-only-cancer-immunotherapy-for-initial-treatment-of-difficult-to-treat-type-of-lung-cancer"> FDA Approves First and Only Cancer Immunotherapy for Initial Treatment of Difficult-to-Treat Type of Lung Cancer </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/tecentriq"> Tecentriq </a> <p class="media-list-feature__excerpt">On March 18, 2019, the FDA approved Genentech&rsquo;s immunotherapy, in combination with chemotherapy (carboplatin and etoposide), for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-first-and-only-cancer-immunotherapy-for-initial-treatment-of-difficult-to-treat-type-of-lung-cancer/Tecentriq_SCLC_Media_Kit_2019-03-18.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a>  |  <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-first-and-only-cancer-immunotherapy-for-initial-treatment-of-difficult-to-treat-type-of-lung-cancer/tecentriq_broll_package_2019-03-20.mp4.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download B-Roll</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/genentech-medicine-fda-approved-as-first-cancer-immunotherapy-for-a-type-of-breast-cancer"> <img src="/assets/content/news_feature_thumbnail/1048_Tecentriq+TNBC+News+Feature_Media+Thumbnail+Image_340x340_v1.png" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">8 Mar 2019</p> <a class="media-list-feature__title" href="/media/news-features/genentech-medicine-fda-approved-as-first-cancer-immunotherapy-for-a-type-of-breast-cancer"> Genentech Medicine FDA Approved as First Cancer Immunotherapy for a Type of Breast Cancer </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/tecentriq"> Tecentriq </a> <p class="media-list-feature__excerpt">On March 8, 2019, the FDA granted accelerated approval to a Genentech medicine for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer in people whose tumors express PD-L1, as determined by an FDA-approved test.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/genentech-medicine-fda-approved-as-first-cancer-immunotherapy-for-a-type-of-breast-cancer/tecentriq_media_kit_2019_03_08.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/genentech-announces-alexander-hardy-as-chief-executive-officer"> <img src="/assets/content/news_feature_thumbnail/alexander_hardy_ceo_news_feature_thumbnail_340x340.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">24 Jan 2019</p> <a class="media-list-feature__title" href="/media/news-features/genentech-announces-alexander-hardy-as-chief-executive-officer"> Genentech Announces Alexander Hardy As Chief Executive Officer </a> <p class="media-list-feature__excerpt">Genentech, a member of the Roche Group, today announced the appointment of Alexander Hardy to chief executive officer, effective March 1, 2019.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/genentech-announces-alexander-hardy-as-chief-executive-officer/Genentech_CEO_Announcement_Media_Kit_2019-01-24.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/fda-approves-new-immunotherapy-combination-for-a-specific-type-of-metastatic-lung-cancer"> <img src="/assets/content/news_feature_thumbnail/0450_tecentriq_impower150_news_feature_news_feature_thumbnail_18-12-06_340x340.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">6 Dec 2018</p> <a class="media-list-feature__title" href="/media/news-features/fda-approves-new-immunotherapy-combination-for-a-specific-type-of-metastatic-lung-cancer"> FDA Approves New Immunotherapy Combination for a Specific Type of Metastatic Lung Cancer </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/tecentriq"> Tecentriq </a> <p class="media-list-feature__excerpt">On December 6, 2018, the FDA granted approval to a new immunotherapy combination for the initial treatment of people with metastatic non-squamous non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-new-immunotherapy-combination-for-a-specific-type-of-metastatic-lung-cancer/Tecentriq_Media_Kit_2018-12-06.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/fda-approves-new-treatment-option-for-people-newly-diagnosed-with-acute-myeloid-leukemia"> <img src="/assets/content/news_feature_thumbnail/1042_Venclexta_AML_news_feature_thumbnail_18-11-19_340x340.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">21 Nov 2018</p> <a class="media-list-feature__title" href="/media/news-features/fda-approves-new-treatment-option-for-people-newly-diagnosed-with-acute-myeloid-leukemia"> FDA Approves New Treatment Option for People Newly-Diagnosed With Acute Myeloid Leukemia </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/venclexta"> Venclexta </a> <p class="media-list-feature__excerpt">On November 21, 2018, the FDA approved a Genentech medicine, in combination with azacitidine, or decitabine, or LDAC, for people newly-diagnosed with AML who are age 75 years or older, or who are ineligible for intensive chemotherapy due to coexisting medical conditions. This indication is approved under accelerated approval based on response rates. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-new-treatment-option-for-people-newly-diagnosed-with-acute-myeloid-leukemia/Venclexta_AML_Media_Kit_2018-11-21.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/fda-approves-new-single-dose-treatment-for-influenza"> <img src="/assets/content/news_feature_thumbnail/1036_Xofluza_news-feature_thumbnail_340x340.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">24 Oct 2018</p> <a class="media-list-feature__title" href="/media/news-features/fda-approves-new-single-dose-treatment-for-influenza"> FDA Approves New Single-dose Treatment For Influenza </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/xofluza"> Xofluza </a> <p class="media-list-feature__excerpt">On October 24, 2018, the FDA approved the first and only single-dose, oral antiviral medicine to treat the flu.聽</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-new-single-dose-treatment-for-influenza/xofluza_media_kit_2022-08-17.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a>  |  <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-new-single-dose-treatment-for-influenza/xofluza_broll_2022-08-15.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download B-Roll</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/fda-approves-new-prophylactic-treatment-for-hemophilia-a-without-factor-viii-inhibitors"> <img src="/assets/content/news_feature_thumbnail/1033_hemlibra-news-feature_thumbnail_340x340.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">4 Oct 2018</p> <a class="media-list-feature__title" href="/media/news-features/fda-approves-new-prophylactic-treatment-for-hemophilia-a-without-factor-viii-inhibitors"> FDA Approves New Prophylactic Treatment For Hemophilia A Without Factor VIII Inhibitors </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/hemlibra"> Hemlibra </a> <p class="media-list-feature__excerpt">On October 4, 2018, the FDA approved a Genentech medicine as a new prophylactic (preventative) treatment for adults and children, ages newborn and older, with hemophilia A without factor VIII inhibitors, making it the only approved medicine for hemophilia A with and without factor VIII inhibitors that can be self-administered under the skin (subcutaneously) once weekly, every two weeks or every four weeks.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-new-prophylactic-treatment-for-hemophilia-a-without-factor-viii-inhibitors/Hemlibra_Media_Kit_2018-10-04.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a>  |  <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-new-prophylactic-treatment-for-hemophilia-a-without-factor-viii-inhibitors/hemlibra_broll_package_2018-10-04.mp4.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download B-Roll</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/fda-approves-genentech-s-avastin-bevacizumab-plus-chemotherapy-as-a-treatment-for-women-with-advanced-ovarian-cancer-following-initial-surgery"> <img src="/assets/content/news_feature_thumbnail/1018_Avastin_advanced_ovarian_cancer_news-feature_thumbnail_340x340.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">13 Jun 2018</p> <a class="media-list-feature__title" href="/media/news-features/fda-approves-genentech-s-avastin-bevacizumab-plus-chemotherapy-as-a-treatment-for-women-with-advanced-ovarian-cancer-following-initial-surgery"> FDA Approves Genentech鈥檚 Avastin庐 (Bevacizumab) Plus Chemotherapy as a Treatment for Women with Advanced Ovarian Cancer Following Initial Surgery </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/avastin"> Avastin </a> <p class="media-list-feature__excerpt">On June 13, 2018 the FDA approved a Genentech medicine for the treatment of women with advanced (stage III or IV) epithelial ovarian, fallopian tube or primary peritoneal cancer following initial surgical resection.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-genentech-s-avastin-bevacizumab-plus-chemotherapy-as-a-treatment-for-women-with-advanced-ovarian-cancer-following-initial-surgery/Avastin_Media_Kit_2018-06-13.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/fda-approves-new-treatment-option-for-previously-treated-chronic-lymphocytic-leukemia"> <img src="/assets/content/news_feature_thumbnail/1020_Venclexta_Murano_Approval_Newafeature_thumbnail_340x340.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">8 Jun 2018</p> <a class="media-list-feature__title" href="/media/news-features/fda-approves-new-treatment-option-for-previously-treated-chronic-lymphocytic-leukemia"> FDA Approves New Treatment Option for Previously Treated Chronic Lymphocytic Leukemia </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/venclexta"> Venclexta </a> <p class="media-list-feature__excerpt">On June 8, 2018, the FDA approved a Genentech medicine for people with previously treated chronic lymphocytic leukemia.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-new-treatment-option-for-previously-treated-chronic-lymphocytic-leukemia/Venclexta_Media_Kit_2018-06-08.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/fda-approves-new-treatment-option-for-adjuvant-treatment-of-specific-type-of-early-breast-cancer"> <img src="/assets/content/news_feature_thumbnail/1014_perjeta-aphinity_media_news-feature-thumbnail_v2_340x340_op.png" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">20 Dec 2017</p> <a class="media-list-feature__title" href="/media/news-features/fda-approves-new-treatment-option-for-adjuvant-treatment-of-specific-type-of-early-breast-cancer"> FDA Approves New Treatment Option for Adjuvant Treatment of Specific Type of Early Breast Cancer </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/perjeta"> Perjeta </a> <p class="media-list-feature__excerpt">On December 20, 2017, the FDA approved a Genentech medicine for adjuvant (after surgery) treatment of HER2-positive early breast cancer at high risk of recurrence.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-new-treatment-option-for-adjuvant-treatment-of-specific-type-of-early-breast-cancer/Perjeta_adjuvant_Media_Kit_12-2017.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a>  |  <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-new-treatment-option-for-adjuvant-treatment-of-specific-type-of-early-breast-cancer/Perjeta_adjuvant_Broll_Package_12-2017_v13.mp4.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download B-Roll</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/fda-approves-new-treatment-option-for-previously-untreated-advanced-follicular-lymphoma"> <img src="/assets/content/news_feature_thumbnail/1010_gazyva_media_news-feature_thumbnail_340x340_op.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">16 Nov 2017</p> <a class="media-list-feature__title" href="/media/news-features/fda-approves-new-treatment-option-for-previously-untreated-advanced-follicular-lymphoma"> FDA Approves New Treatment Option for Previously Untreated Advanced Follicular Lymphoma </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/gazyva"> Gazyva </a> <p class="media-list-feature__excerpt">On November 16, 2017, the FDA approved a Genentech medicine as a treatment option for people with previously untreated advanced follicular lymphoma (stage II bulky, III or IV).</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-new-treatment-option-for-previously-untreated-advanced-follicular-lymphoma/Gazyva_MediaKit_11-16-17.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/fda-approves-new-once-weekly-prophylactic-treatment-for-hemophilia-a-with-inhibitors"> <img src="/assets/content/news_feature_thumbnail/0338_hemlibra_media_news-feature_thumbnail_340x340_op.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">16 Nov 2017</p> <a class="media-list-feature__title" href="/media/news-features/fda-approves-new-once-weekly-prophylactic-treatment-for-hemophilia-a-with-inhibitors"> FDA Approves New Once-Weekly Prophylactic Treatment For Hemophilia A With Inhibitors </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/hemlibra"> Hemlibra </a> <p class="media-list-feature__excerpt">On November 16, the FDA approved a Genentech medicine as a prophylactic (preventative) treatment for adults and children with hemophilia A with factor VIII inhibitors that can be self-administered once weekly by injection under the skin (subcutaneously).</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-new-once-weekly-prophylactic-treatment-for-hemophilia-a-with-inhibitors/Hemlibra_MediaKit_11-16-17.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a>  |  <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-new-once-weekly-prophylactic-treatment-for-hemophilia-a-with-inhibitors/hemlibra_broll.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download B-Roll</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/fda-approves-genentech-medicine-for-first-line-treatment-of-specific-type-of-lung-cancer"> <img src="/assets/content/news_feature_thumbnail/Alecensa_Media-Tile_340x340.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">6 Nov 2017</p> <a class="media-list-feature__title" href="/media/news-features/fda-approves-genentech-medicine-for-first-line-treatment-of-specific-type-of-lung-cancer"> FDA Approves Genentech Medicine for First-Line Treatment of Specific Type of Lung Cancer </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/alecensa"> Alecensa </a> <p class="media-list-feature__excerpt">On November 6, 2017, the FDA approved a Genentech medicine for the treatment of people with a specific type of lung cancer.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-genentech-medicine-for-first-line-treatment-of-specific-type-of-lung-cancer/Alecensa_MediaKit_11-06-17.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/fda-approves-new-time-saving-treatment-option-for-people-with-certain-blood-cancers"> <img src="/assets/content/news_feature_thumbnail/0305_rituxan_hycela-approval_news-feature_Thumbnail_340x340.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">22 Jun 2017</p> <a class="media-list-feature__title" href="/media/news-features/fda-approves-new-time-saving-treatment-option-for-people-with-certain-blood-cancers"> FDA Approves New Time-Saving Treatment Option for People with Certain Blood Cancers </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/rituxan-hycela"> Rituxan Hycela </a> <p class="media-list-feature__excerpt">On June 22, 2017, the FDA approved a Genentech medicine for subcutaneous (under the skin) injection for the treatment of certain blood cancers.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-new-time-saving-treatment-option-for-people-with-certain-blood-cancers/Rituxan_Hycela_MediaKit_06-22-17.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit </a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/fda-approves-new-option-for-certain-people-with-advanced-bladder-cancer"> <img src="/assets/content/news_feature_thumbnail/0240_Tecentriq_1L-mUC-approval_news-feature_Thumbnail_340x340.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">17 Apr 2017</p> <a class="media-list-feature__title" href="/media/news-features/fda-approves-new-option-for-certain-people-with-advanced-bladder-cancer"> FDA Approves New Option for Certain People with Advanced Bladder Cancer </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/tecentriq"> Tecentriq </a> <p class="media-list-feature__excerpt">On April 17, 2017, the FDA granted accelerated approval to a Genentech cancer immunotherapy medicine as an initial treatment for certain people with advanced bladder cancer.</p> <div class="media-list-feature__links"> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/fda-approves-new-treatment-option-for-people-with-diabetic-retinopathy"> <img src="/assets/content/news_feature_thumbnail/0257_DiabeticRetinopathy_newsfeature_thumb_340x340.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">17 Apr 2017</p> <a class="media-list-feature__title" href="/media/news-features/fda-approves-new-treatment-option-for-people-with-diabetic-retinopathy"> FDA Approves New Treatment Option for People with Diabetic Retinopathy </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/lucentis"> Lucentis </a> <p class="media-list-feature__excerpt">On April 17, 2017, the FDA granted approval to a Genentech medicine for the monthly treatment of all forms of diabetic retinopathy, a potentially blinding eye disease.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-new-treatment-option-for-people-with-diabetic-retinopathy/Lucentis_MediaKit_04-17-17_v1.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/fda-approves-medicine-for-women-with-platinum-sensitive-recurrent-ovarian-cancer"> <img src="/assets/content/news_feature_thumbnail/avastin_news_feature_thumbnail.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">6 Dec 2016</p> <a class="media-list-feature__title" href="/media/news-features/fda-approves-medicine-for-women-with-platinum-sensitive-recurrent-ovarian-cancer"> FDA Approves Medicine for Women with Platinum-Sensitive Recurrent Ovarian Cancer </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/avastin"> Avastin </a> <p class="media-list-feature__excerpt">On December&nbsp;6, 2016 the FDA approved a medicine for women with platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-medicine-for-women-with-platinum-sensitive-recurrent-ovarian-cancer/Avastin_psOC_MediaKit_12-08-17.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/fda-approves-new-immunotherapy-medicine-for-a-type-of-metastatic-lung-cancer"> <img src="/assets/content/news_feature_thumbnail/Tecentriq_NSCLC_newsfeature_section-tile_340x340.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">18 Oct 2016</p> <a class="media-list-feature__title" href="/media/news-features/fda-approves-new-immunotherapy-medicine-for-a-type-of-metastatic-lung-cancer"> FDA Approves New Immunotherapy Medicine for a Type of Metastatic Lung Cancer </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/tecentriq"> Tecentriq </a> <p class="media-list-feature__excerpt">On October 18, 2016, the FDA granted approval to a new cancer immunotherapy medicine for the treatment of a type of metastatic lung cancer.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-new-immunotherapy-medicine-for-a-type-of-metastatic-lung-cancer/Tecentriq_NSCLC_mediakit_10-18-16_v1.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a>  |  <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-new-immunotherapy-medicine-for-a-type-of-metastatic-lung-cancer/Tecentriq_NSCLC_Approval_B-roll.mp4.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download B-Roll</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/flu-season"> <img src="/assets/content/news_feature_thumbnail/cb1f8532347.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">16 Sep 2016</p> <a class="media-list-feature__title" href="/media/news-features/flu-season"> Flu Season Resources </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/tamiflu"> Tamiflu </a> <p class="media-list-feature__excerpt">On average, 5-20% of the US population gets the flu each year, and more than 200,000 are hospitalized from seasonal flu related complications. To recognize flu symptoms, remember Flu F.A.C.T.S. (Fever, Aches, Chills, (extreme) Tiredness, and Sudden Onset).</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/flu-season/Flu_MediaKit_2016.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a>  |  <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/flu-season/Tamilflu_newsfeature_OS_Seasonal_BRoll_November-2016.mp4.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download B-Roll</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/fda-approves-new-immunotherapy-medicine-for-specific-type-of-advanced-bladder-cancer"> <img src="/assets/content/news_feature_thumbnail/tecentriq_newsroom_section-tile_340x340.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">18 May 2016</p> <a class="media-list-feature__title" href="/media/news-features/fda-approves-new-immunotherapy-medicine-for-specific-type-of-advanced-bladder-cancer"> FDA Approves New Immunotherapy Medicine for Specific Type of Advanced Bladder Cancer </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/tecentriq"> Tecentriq </a> <p class="media-list-feature__excerpt">On May 18, 2016, the FDA granted accelerated approval to a new cancer immunotherapy medicine for the treatment of a specific type of advanced bladder cancer.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-new-immunotherapy-medicine-for-specific-type-of-advanced-bladder-cancer/tecentriq_newsfeature_mediakit_05-18-16.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a>  |  <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-new-immunotherapy-medicine-for-specific-type-of-advanced-bladder-cancer/tecentriq_newsfeature_broll_05-19-16.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download B-Roll</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/fda-approves-new-treatment-option-for-hard-to-treat-type-of-chronic-lymphocytic-leukemia"> <img src="/assets/content/news_feature_thumbnail/venclexta_newsroom_section-tile_340x340.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">11 Apr 2016</p> <a class="media-list-feature__title" href="/media/news-features/fda-approves-new-treatment-option-for-hard-to-treat-type-of-chronic-lymphocytic-leukemia"> FDA Approves New Treatment Option for Hard-To-Treat Type of Chronic Lymphocytic Leukemia </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/venclexta"> Venclexta </a> <p class="media-list-feature__excerpt">On April 11, 2016, the FDA granted accelerated approval to a new medicine for the treatment of a hard-to-treat type of chronic lymphocytic leukemia.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-new-treatment-option-for-hard-to-treat-type-of-chronic-lymphocytic-leukemia/venclexta_newsfeature_mediakit_04-11-16.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/fda-approves-new-option-for-certain-people-with-previously-treated-follicular-lymphoma"> <img src="/assets/content/news_feature_thumbnail/Gazyva_NHL_Newsfeature_Thumbnail_340x340.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">26 Feb 2016</p> <a class="media-list-feature__title" href="/media/news-features/fda-approves-new-option-for-certain-people-with-previously-treated-follicular-lymphoma"> FDA Approves New Option For Certain People With Previously Treated Follicular Lymphoma </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/gazyva"> Gazyva </a> <p class="media-list-feature__excerpt">On February 26, 2016, the FDA approved a Genentech medicine for people with follicular lymphoma whose disease did not respond to or returned after treatment with another medicine.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-new-option-for-certain-people-with-previously-treated-follicular-lymphoma/Gazyva_NHL_Newsfeature_MediaKit_03-10-16.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/fda-approves-new-treatment-option-for-specific-type-of-lung-cancer"> <img src="/assets/content/news_feature_thumbnail/Alecensa_newsroom_SectionTile_340x340.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">11 Dec 2015</p> <a class="media-list-feature__title" href="/media/news-features/fda-approves-new-treatment-option-for-specific-type-of-lung-cancer"> FDA Approves New Treatment Option for Specific Type of Lung Cancer </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/alecensa"> Alecensa </a> <p class="media-list-feature__excerpt">On December 11, 2015, the FDA granted accelerated approval to a new medicine for the treatment of a specific type of lung cancer.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-new-treatment-option-for-specific-type-of-lung-cancer/Alecensa_NSCLC_mediakit_03-08-17.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/fda-approves-new-treatment-option-for-advanced-melanoma"> <img src="/assets/content/news_feature_thumbnail/7FfEnfdKuO5N8nSzPn6pqUzeaHjMuvD8.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">10 Nov 2015</p> <a class="media-list-feature__title" href="/media/news-features/fda-approves-new-treatment-option-for-advanced-melanoma"> FDA Approves New Treatment Option for Advanced Melanoma </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/cotellic"> Cotellic </a> <p class="media-list-feature__excerpt">On November 10, 2015, the FDA approved&nbsp;a new medicine for the treatment of advanced melanoma.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-new-treatment-option-for-advanced-melanoma/Cotellic_Product_Images_October-2016.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Product Images</a>  |  <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-new-treatment-option-for-advanced-melanoma/Cotellic_Zelboraf_MOA-October-2016.pdf.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download MOA Images</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/fda-approves-genentech-medicine-for-diabetic-retinopathy"> <img src="/assets/content/news_feature_thumbnail/14b6094f911.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">6 Feb 2015</p> <a class="media-list-feature__title" href="/media/news-features/fda-approves-genentech-medicine-for-diabetic-retinopathy"> FDA Approves Genentech Medicine for Diabetic Retinopathy in People with Diabetic Macular Edema </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/lucentis"> Lucentis </a> <p class="media-list-feature__excerpt">On February 6, 2015, the FDA approved a Genentech Medicine for the treatment of diabetic retinopathy in people with diabetic macular edema (DME).</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/Lucentis_Commercial_3mg_Box_Vial_4C_FIN[2].jpg"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Product Image</a>  |  <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/Lucentis_DR_Broll_02-10-15.mp4.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download B-Roll</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/genentech-medicine-fda-approved-for-ovarian-cancer"> <img src="/assets/content/news_feature_thumbnail/149af9867b0.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">14 Nov 2014</p> <a class="media-list-feature__title" href="/media/news-features/genentech-medicine-fda-approved-for-ovarian-cancer"> FDA Approves Genentech Medicine for Women with Platinum-Resistant Recurrent Ovarian Cancer </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/avastin"> Avastin </a> <p class="media-list-feature__excerpt">On November 14, 2014, a Genentech medicine received FDA approval for the treatment of women with platinum-resistant, recurrent, epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received no more than two prior chemotherapy regimens.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/Avastin_Ovarian_MediaKit_11-14-14.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a>  |  <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/Avastin_Ovarian_Broll_11-14-14.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download B-Roll</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/medicine-fda-approved-for-idiopathic-pulmonary-fibrosis"> <img src="/assets/content/news_feature_thumbnail/cda9ba5b800.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">15 Oct 2014</p> <a class="media-list-feature__title" href="/media/news-features/medicine-fda-approved-for-idiopathic-pulmonary-fibrosis"> FDA Approves Medicine for Idiopathic Pulmonary Fibrosis </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/esbriet"> Esbriet </a> <p class="media-list-feature__excerpt">On October 15, 2014, the FDA approved a medicine for the treatment of idiopathic pulmonary fibrosis (IPF).</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/fda-approves-medicine-for-idiopathic-pulmonary-fibrosis/esbriet_productshot_02-22-16.png"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Product Image</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/genentech-medicine-fda-approved-for-cervical-cancer"> <img src="/assets/content/news_feature_thumbnail/147d6539a07.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">14 Aug 2014</p> <a class="media-list-feature__title" href="/media/news-features/genentech-medicine-fda-approved-for-cervical-cancer"> FDA Approves Genentech Medicine for Women with Advanced Cervical Cancer </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/avastin"> Avastin </a> <p class="media-list-feature__excerpt">On August 14, 2014, a Genentech medicine received FDA approval for use in persistent, recurrent or metastatic cervical cancer. It is the first biologic medicine approved in combination with chemotherapy to help women with this type of cancer live longer than with chemotherapy alone.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/Avastin_Cervical_MediaKit_08-14-2014_v2.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a>  |  <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/Avastin_Cervical_Broll_08-14-2014.mov.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download B-Roll</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/seragon-acquisition"> <img src="/assets/content/news_feature_thumbnail/146ef8ba2d4.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">1 Jul 2014</p> <a class="media-list-feature__title" href="/media/news-features/seragon-acquisition"> Genentech Announces Definitive Agreement to Acquire Seragon Pharmaceuticals </a> <p class="media-list-feature__excerpt">On July 1, 2014, Genentech entered into an agreement to acquire Seragon Pharmaceuticals, Inc., a privately held biotechnology company based in San Diego, California.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media_asset_interceptor_cancer_cell.jpg"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Related Image</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/fda-approval-ciu"> <img src="/assets/content/news_feature_thumbnail/144fb46fe8c.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">21 Mar 2014</p> <a class="media-list-feature__title" href="/media/news-features/fda-approval-ciu"> FDA Approves Xolair庐 (omalizumab) for Subcutaneous Use for People with Chronic Idiopathic Urticaria (CIU), a Form of Chronic Hives </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/xolair"> Xolair </a> <p class="media-list-feature__excerpt">On March 21, 2014, the FDA approved a Genentech medicine for people 12 years of age and older for the treatment of chronic idiopathic urticaria (CIU), a form of chronic hives.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/xolair_mediakit.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/genentech-at-ash-2013"> <img src="/assets/content/news_feature_thumbnail/cb1f850b46c.jpeg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">5 Dec 2013</p> <a class="media-list-feature__title" href="/media/news-features/genentech-at-ash-2013"> ASH 2013: Press Releases, Fact Sheets & More </a> <p class="media-list-feature__excerpt">We're presenting important new findings on unapproved and investigational medicines at ASH 2013. Read press releases and learn about our presence at ASH this year.</p> <div class="media-list-feature__links"> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/fda-approval-CLL"> <img src="/assets/content/news_feature_thumbnail/cb1f8628dca.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">1 Nov 2013</p> <a class="media-list-feature__title" href="/media/news-features/fda-approval-CLL"> FDA Approves New Genentech Medicine for Chronic Lymphocytic Leukemia (CLL) </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/gazyva"> Gazyva </a> <p class="media-list-feature__excerpt">On November 1, 2013, the FDA approved a new Genentech medicine for people with previously untreated CLL. It was the first medicine approved with the FDA&rsquo;s Breakthrough Therapy Designation.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/Gazyva_CLL_mediakit_03-26-2015.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/genentech-at-asco-2013"> <img src="/assets/content/news_feature_thumbnail/208a35f469.png" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">15 May 2013</p> <a class="media-list-feature__title" href="/media/news-features/genentech-at-asco-2013"> 2013 ASCO Annual Meeting </a> <p class="media-list-feature__excerpt">Genentech to report new advances at the American Society of Clinical Oncology Annual MeetingGenentech will present important new data from studies of several cancer medicines at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) from May 31-June 4, 2013, in Chicago.This page is intended to be a media resource for Genentech developments at ASCO. It will be updated frequently throughout the meeting.</p> <div class="media-list-feature__links"> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/tarceva-approval-nsclc"> <img src="/assets/content/news_feature_thumbnail/145664680eb.png" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">14 May 2013</p> <a class="media-list-feature__title" href="/media/news-features/tarceva-approval-nsclc"> FDA Approves First Personalized Medicine for EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer in the United States </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/tarceva"> Tarceva </a> <p class="media-list-feature__excerpt">On May 14, 2013, the FDA approved a personalized medicine for people newly diagnosed with a genetically distinct type of metastatic NSCLC.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/tarceva_mediakit.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/celebrating-wc"> <img src="/assets/content/news_feature_thumbnail/cb5fedd7c82.png" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">10 May 2013</p> <a class="media-list-feature__title" href="/media/news-features/celebrating-wc"> Celebrating the 60th Anniversary of Watson & Crick鈥檚 Discovery </a> <p class="media-list-feature__excerpt">Genentech built an iPad app that turns a primary genetic concept into a maddeningly addictive mobile game.</p> <div class="media-list-feature__links"> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/avastin-fda-approval"> <img src="/assets/content/news_feature_thumbnail/cb602ccb8b4.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">23 Jan 2013</p> <a class="media-list-feature__title" href="/media/news-features/avastin-fda-approval"> FDA Approves New Use of Avastin Plus Fluoropyrimidine-Based Chemotherapy in Metastatic Colorectal Cancer </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/avastin"> Avastin </a> <p class="media-list-feature__excerpt">On January 23, 2013, a Genentech medicine received FDA approval for a new use in metastatic colorectal cancer.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/avastin_mediakit.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a>  |  <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/avastin_broll.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download B-Roll</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/news-actemra-expansion"> <img src="/assets/content/news_feature_thumbnail/cb6030690f9.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">12 Oct 2012</p> <a class="media-list-feature__title" href="/media/news-features/news-actemra-expansion"> FDA Approves Expanded Indication for Actemra in RA </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/actemra"> Actemra </a> <p class="media-list-feature__excerpt">On October 12, 2012, a Genentech medicine received approval from the FDA to expand its indication for Rheumatoid Arthritis.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/actemra_media.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/genentech-gride-program-achieves-landmark-milestone"> <img src="/assets/content/news_feature_thumbnail/cb6032c6419.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">25 Aug 2012</p> <a class="media-list-feature__title" href="/media/news-features/genentech-gride-program-achieves-landmark-milestone"> Genentech's gRide Program Achieves Landmark Milestone </a> <p class="media-list-feature__excerpt">gRide, Genentech's employee commuting program, has saved 100 million miles of driving since the program's inception began in late 2006. The program began as a way to reduce the number of vehicles that travel to and park on the South San Francisco campus.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/100MM_all_mediakit.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a>  |  <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/100MM_broll.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download B-Roll</a>  |  <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/100MM_GenenBus.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Images</a>  |  <a class="media-list-feature__link" href="/assets/frontend/img/content/media/news-features/100-million-miles-saved_infographic.png"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Infographic</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <div class="media-list-feature__body"> <p class="media-list-feature__date">10 Aug 2012</p> <a class="media-list-feature__title" href="/media/news-features/news-lucentis-dme"> Lucentis Approved for Treatment of Diabetic Macular Edema (DME) </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/lucentis"> Lucentis </a> <p class="media-list-feature__excerpt">On August 10, 2012, a Genentech medicine was approved by the FDA for diabetic macular edema (DME).</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/lucentis_media.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a>  |  <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/lucentis_broll.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Lucentis B-Roll</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/genentech-gives-back-week-2012"> <img src="/assets/content/news_feature_thumbnail/cb603cf8113.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">11 Jun 2012</p> <a class="media-list-feature__title" href="/media/news-features/genentech-gives-back-week-2012"> Genentech Gives Back Week 2012 </a> <p class="media-list-feature__excerpt">Genentech Gives Back Week (June 11 - 16, 2012) is a unique opportunity for Genentech employees to support the communities where we live and work.</p> <div class="media-list-feature__links"> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/perjeta-approved-for-her2-positive-metastatic-breast-cancer"> <img src="/assets/content/news_feature_thumbnail/cb609994601.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">8 Jun 2012</p> <a class="media-list-feature__title" href="/media/news-features/perjeta-approved-for-her2-positive-metastatic-breast-cancer"> Perjeta Approved For HER2-Positive Metastatic Breast Cancer </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/perjeta"> Perjeta </a> <p class="media-list-feature__excerpt">On June 8, 2012, a Genentech medicine was approved by the FDA for previously untreated HER2-positive metastatic breast cancer.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/perjeta-approved-for-her2-positive-metastatic-breast-cancer/perjeta_media.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Logo and Product Packaging</a>  |  <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/perjeta-approved-for-her2-positive-metastatic-breast-cancer/perjeta_moa_images.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Perjeta Mechanism of Action (MOA)</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <div class="media-list-feature__body"> <p class="media-list-feature__date">30 May 2012</p> <a class="media-list-feature__title" href="/media/news-features/genentech-at-asco-2012"> Genentech at ASCO 2012 </a> <p class="media-list-feature__excerpt">Genentech will present important new data on several cancer medicines at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO).</p> <div class="media-list-feature__links"> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/landmark-alzheimers-prevention-trial"> <img src="/assets/content/news_feature_thumbnail/cb636c3cc83.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">17 May 2012</p> <a class="media-list-feature__title" href="/media/news-features/landmark-alzheimers-prevention-trial"> Landmark Alzheimer's Prevention Trial </a> <p class="media-list-feature__excerpt">Genentech, the Banner Alzheimer's Institute, and the National Institutes of Health are collaborating on the first-ever prevention trial in cognitively healthy individuals who are likely to develop Alzheimer's disease due to their genetic history.</p> <div class="media-list-feature__links"> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/erivedge-approved-for-advanced-basal-cell-carcinoma"> <img src="/assets/content/news_feature_thumbnail/1456be44565.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">30 Jan 2012</p> <a class="media-list-feature__title" href="/media/news-features/erivedge-approved-for-advanced-basal-cell-carcinoma"> Erivedge Approved For Advanced Basal Cell Carcinoma </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/erivedge"> Erivedge </a> <p class="media-list-feature__excerpt">On January 30, 2012, a Genentech medicine was approved by the FDA for the treatment of adults with a type of skin cancer, called basal cell carcinoma (BCC), that has spread to other parts of the body or that has come back after surgery or that their healthcare provider decides cannot be treated with surgery or radiation.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/erivedge_media.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Media Kit</a>  |  <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/erivedge_moa.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Erivedge Mechanism of Action (MOA)</a>  |  <a class="media-list-feature__link" href="https://www.gene.com/assets/frontend/downloads/media/news-features/bcc.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download BCC Images</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/genentech-medicine-approved-for-certain-type-of-melanoma"> <img src="/assets/content/news_feature_thumbnail/cbe71b69dda.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">17 Aug 2011</p> <a class="media-list-feature__title" href="/media/news-features/genentech-medicine-approved-for-certain-type-of-melanoma"> Genentech Medicine Approved For Certain Type Of Melanoma </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/zelboraf"> Zelboraf </a> <p class="media-list-feature__excerpt">On August 17, 2011, a Genentech medicine was approved by the FDA for a type of inoperable or metastatic melanoma.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/zelboraf_media.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Zelboraf Logo, Pills, and Packaging</a>  |  <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/zelboraf_moa.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Zelboraf Mechanism of Action (MOA)</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/genentech-medicine-approved-in-stomach-cancer"> <img src="/assets/content/news_feature_thumbnail/1463e976844.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">20 Oct 2010</p> <a class="media-list-feature__title" href="/media/news-features/genentech-medicine-approved-in-stomach-cancer"> Genentech Medicine Approved in Stomach Cancer </a> <a class="media-list-feature__product" style="display:none;" href="/patients/medicines/herceptin"> Herceptin </a> <p class="media-list-feature__excerpt">On October 20, 2010, a Genentech medicine was approved by the U.S. Food and Drug Administration (FDA) for stomach cancer.</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/stomach_cancer_broll.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Stomach Cancer B-Roll</a>  |  <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/herceptin_media.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Images (Media Kit)</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <div class="media-list-feature__body"> <p class="media-list-feature__date">18 Oct 2010</p> <a class="media-list-feature__title" href="/media/news-features/25th-anniversary-of-first-product-approval"> 25th Anniversary of First Product Approval </a> <p class="media-list-feature__excerpt">October 18, 2010 is the 25th anniversary of Genentech's first product approval and the first recombinant biotech drug to be manufactured and marketed by a biotechnology company.</p> <div class="media-list-feature__links"> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <div class="media-list-feature__body"> <p class="media-list-feature__date">21 Sep 2010</p> <a class="media-list-feature__title" href="/media/news-features/napoleone-ferrara-named-2010-lasker-award-winner"> Napoleone Ferrara Named 2010 Lasker Award Winner </a> <p class="media-list-feature__excerpt">Genentech Fellow Napoleone Ferrara is the winner of the 2010 Lasker Award for clinical research, presented annually to an investigator "whose contributions have improved the clinical treatment of patients."</p> <div class="media-list-feature__links"> <a class="media-list-feature__link" href="/assets/frontend/pdf/content/media/news-features/napoleone-ferrara-named-2010-lasker-award-winner_PressRelease.pdf"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Press Release</a>  |  <a class="media-list-feature__link" href="/assets/frontend/downloads/media/news-features/erivedge_media.zip"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-download"></use> </svg> Download Photo</a> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <div class="media-list-feature__body"> <p class="media-list-feature__date">13 Sep 2010</p> <a class="media-list-feature__title" href="/media/news-features/genentech-goes-to-town-2010"> Genentech Goes to Town 2010 </a> <p class="media-list-feature__excerpt">Genentech Goes to Town takes place September 13 to September 24 in South San Francisco, Vacaville, Oceanside and Hillsboro. The Genentech Goes to Town program supports our communities by providing employees with special "GenenMoney" to spend at local businesses.</p> <div class="media-list-feature__links"> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> <tr> <td class="media-list-feature"> <a class="media-list-feature__image" href="/media/news-features/genentech-gives-back-week-2010"> <img src="/assets/content/news_feature_thumbnail/1463e73eaea.jpg" /> </a> <div class="media-list-feature__body"> <p class="media-list-feature__date">14 Jun 2010</p> <a class="media-list-feature__title" href="/media/news-features/genentech-gives-back-week-2010"> Genentech Gives Back Week 2010 </a> <p class="media-list-feature__excerpt">Genentech Gives Back Week voluntary activities each day that help Genentech employees collectively make a difference in our communities. All employees are invited to participate in Genentech Gives Back as their time and interest allows. </p> <div class="media-list-feature__links"> </div> </div> <div class="media-list-feature__divider"></div> </td> </tr> </tbody> </table> </div> <div class="l-rail-right"> <div class=""> <div class="tile-grid"> <div class="tile-grid__tile"> <a class="v3-tile v3-tile-image content-tile" href="https://www.gene.com/stories/two-scientists-walk-into-a-bar"> <div class="aspect aspect--3x4@md aspect--3x4@sm aspect--3x4@xs"> <div class="aspect-inner"> <div class="content-tile__wrap tile__wrap height-full"> <div class="content-tile__image fill-parent"> <div class="content-tile__image__container__wrapper" style="height:0; padding-bottom:56.25%; overflow: hidden; position: relative;"> <img class="background--gray--blue-lt fill-parent" src="/assets/content/tile_image/0195_2Scientists_podcast_Tile_980x548.jpg" alt="Two Scientists Walk Into a Bar" /> </div> </div> <div class="content-tile__content"> <h3 class="content-tile__header">Two Scientists Walk Into a Bar</h3> <p class="content-tile__body">Listen to our podcast, where researchers talk about their work answering the toughest questions in human biology.</p> </div> <div class="v3-tile__corner-icon"> </div> </div> </div> </div> </a> </div> </div> </div> </div> </div> </div> </div> </div> <script>window.GeneJs = window.GeneJs || {};GeneJs.currentNode = {"rootNode":{"id":"bed56335-ef16-4e42-9521-54bf30bb83b8","parent_id":"0","title":"Media","node_type":"dynamic","request_path":"media","lang_id":"en","source_translation_id":"86d714bc-f08c-11ed-81d4-0242ac150003","target_id":null,"target_path":"media","meta_description":"Genentech media resources and info for stories in development. Find recent and archived press releases.","url_suffix":"","position":44,"prefix":"For","show_in_secondary_navigation":true,"show_in_header":1,"show_in_footer":1,"secondary_navigation_dynamic_children":false,"include_css":null,"include_js":"media-landing","added_date":"2019-12-19T08:00:00.000000Z","added_by":"admin","updated_date":"2023-11-02T13:21:51.000000Z","header_image":null,"body_html":null,"right_rail_html":null,"published":true,"is_unlisted":false,"hide_secondary_navigation":0,"node_parent":null}};</script><script>window.GeneJs = window.GeneJs || {};GeneJs.secondaryNavNode = {"title":"News Features","requestPath":"media\/news-features","ancestors":[{"id":"bed56335-ef16-4e42-9521-54bf30bb83b8","parent_id":"0","title":"Media","node_type":"dynamic","request_path":"media","lang_id":"en","source_translation_id":"86d714bc-f08c-11ed-81d4-0242ac150003","target_id":null,"target_path":"media","meta_description":"Genentech media resources and info for stories in development. Find recent and archived press releases.","url_suffix":"","position":44,"prefix":"For","show_in_secondary_navigation":true,"show_in_header":1,"show_in_footer":1,"secondary_navigation_dynamic_children":false,"include_css":null,"include_js":"media-landing","added_date":"2019-12-19T08:00:00.000000Z","added_by":"admin","updated_date":"2023-11-02T13:21:51.000000Z","header_image":null,"body_html":null,"right_rail_html":null,"published":true,"is_unlisted":false,"hide_secondary_navigation":0,"node_parent":null}],"shouldShow":true};</script><script>window.GeneJs = window.GeneJs || {};GeneJs.geneHeader = {"topNavNodes":{"3":{"id":"033e314b-6cfd-4977-9449-383a7a165faa","parent_id":"0","title":"Patients","node_type":"static","request_path":"patients","lang_id":"en","source_translation_id":"86a3164e-f08c-11ed-9d94-0242ac150003","target_id":null,"target_path":"","meta_description":"Learn more about our medicines, get help with coverage, and find the right resources for you.","url_suffix":"","position":9,"prefix":"For","show_in_secondary_navigation":true,"show_in_header":1,"show_in_footer":1,"secondary_navigation_dynamic_children":false,"include_css":null,"include_js":null,"added_date":"2019-12-19T08:00:00.000000Z","added_by":"admin","updated_date":"2021-08-25T22:26:19.000000Z","header_image":null,"body_html":null,"right_rail_html":null,"published":true,"is_unlisted":false,"hide_secondary_navigation":0},"9":{"id":"59bd7ce6-7a93-4a5b-8ce4-2044dbb5ce7e","parent_id":"0","title":"Medical Professionals","node_type":"static","request_path":"medical-professionals","lang_id":"en","source_translation_id":"86c029be-f08c-11ed-82a4-0242ac150003","target_id":null,"target_path":"","meta_description":"Innovative clinical science. Improved patient care.","url_suffix":"","position":28,"prefix":"For","show_in_secondary_navigation":true,"show_in_header":1,"show_in_footer":1,"secondary_navigation_dynamic_children":false,"include_css":"","include_js":"","added_date":"2019-12-19T08:00:00.000000Z","added_by":"admin","updated_date":"2019-05-23T21:55:15.000000Z","header_image":null,"body_html":null,"right_rail_html":null,"published":true,"is_unlisted":false,"hide_secondary_navigation":0},"12":{"id":"982193bc-a3aa-11e7-b779-d0431ef1c812","parent_id":"0","title":"Partners","node_type":"blocks","request_path":"partners","lang_id":"en","source_translation_id":"86cf2608-f08c-11ed-a8ab-0242ac150003","target_id":null,"target_path":"","meta_description":null,"url_suffix":"","position":35,"prefix":"For","show_in_secondary_navigation":true,"show_in_header":1,"show_in_footer":1,"secondary_navigation_dynamic_children":false,"include_css":null,"include_js":null,"added_date":"2017-09-28T00:37:55.000000Z","added_by":"admin","updated_date":"2020-02-25T13:02:07.000000Z","header_image":"","body_html":null,"right_rail_html":null,"published":true,"is_unlisted":false,"hide_secondary_navigation":0},"13":{"id":"af5bc686-e327-4030-ade9-a30b7cdde115","parent_id":"0","title":"Scientists","node_type":"blocks","request_path":"scientists","lang_id":"en","source_translation_id":"86d36bd2-f08c-11ed-a4c0-0242ac150003","target_id":null,"target_path":"","meta_description":"Every day our scientists do the work, the relentless incremental labor that could lead to world-changing, life-changing advances.","url_suffix":"","position":41,"prefix":"For","show_in_secondary_navigation":true,"show_in_header":1,"show_in_footer":1,"secondary_navigation_dynamic_children":false,"include_css":null,"include_js":null,"added_date":"2019-12-19T08:00:00.000000Z","added_by":"admin","updated_date":"2021-03-31T23:54:11.000000Z","header_image":null,"body_html":null,"right_rail_html":null,"published":true,"is_unlisted":false,"hide_secondary_navigation":0},"15":{"id":"bed56335-ef16-4e42-9521-54bf30bb83b8","parent_id":"0","title":"Media","node_type":"dynamic","request_path":"media","lang_id":"en","source_translation_id":"86d714bc-f08c-11ed-81d4-0242ac150003","target_id":null,"target_path":"media","meta_description":"Genentech media resources and info for stories in development. Find recent and archived press releases.","url_suffix":"","position":44,"prefix":"For","show_in_secondary_navigation":true,"show_in_header":1,"show_in_footer":1,"secondary_navigation_dynamic_children":false,"include_css":null,"include_js":"media-landing","added_date":"2019-12-19T08:00:00.000000Z","added_by":"admin","updated_date":"2023-11-02T13:21:51.000000Z","header_image":null,"body_html":null,"right_rail_html":null,"published":true,"is_unlisted":false,"hide_secondary_navigation":0},"17":{"id":"c42ede74-e262-422c-aecd-bce16e4a6201","parent_id":"0","title":"Good","node_type":"blocks","request_path":"good","lang_id":"en","source_translation_id":"86d8438c-f08c-11ed-b055-0242ac150003","target_id":null,"target_path":"","meta_description":"Through the everyday, incremental acts of kindness, we can make great things happen for our communities and our patients.","url_suffix":"","position":46,"prefix":"For","show_in_secondary_navigation":true,"show_in_header":1,"show_in_footer":1,"secondary_navigation_dynamic_children":false,"include_css":null,"include_js":null,"added_date":"2019-12-19T08:00:00.000000Z","added_by":"admin","updated_date":"2020-05-12T02:58:56.000000Z","header_image":null,"body_html":null,"right_rail_html":null,"published":true,"is_unlisted":false,"hide_secondary_navigation":0},"20":{"id":"e2b7db24-3c44-11e8-b243-d0431ef1c812","parent_id":"0","title":"Hiring","node_type":"blocks","request_path":"careers","lang_id":"en","source_translation_id":"86dffcc6-f08c-11ed-bb3a-0242ac150003","target_id":null,"target_path":"","meta_description":null,"url_suffix":"","position":58,"prefix":"Now","show_in_secondary_navigation":true,"show_in_header":1,"show_in_footer":1,"secondary_navigation_dynamic_children":false,"include_css":null,"include_js":null,"added_date":"2018-04-10T05:25:19.000000Z","added_by":"admin","updated_date":"2020-07-23T22:52:27.000000Z","header_image":null,"body_html":null,"right_rail_html":null,"published":true,"is_unlisted":false,"hide_secondary_navigation":0}}};</script><div class="primary-footer js-nav-footer clearfix"> <div class="constrained"> <div class="footer-logo-narrow" data-set="footer-logo"> <svg aria-label="Genentech - A Member of the Roche Group"> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-genentech-logo"></use> </svg> </div> <nav class="footer-sitemap"> <ul> <li class="first-level"> <a href="/patients">For Patients</a> </li> <li> <a href="/patients/medicines">Our Medicines</a> </li> <li> <a href="/patients/patient-foundation">Genentech Patient Foundation</a> </li> <li> <a href="/patients/clinical-trials">Clinical Trials</a> </li> <li> <a href="/patients/patient-support-services">Patient Support Services</a> </li> <li> <a href="/patients/understanding-insurance">Understanding Insurance</a> </li> <li> <a href="/patients/medicine-information-support">Medicine Information Support</a> </li> <li> <a href="/patients/giving-patients-a-voice">Giving Patients a Voice</a> </li> <li> <a href="/patients/disease-education">Disease Education</a> </li> </ul> <ul> <li class="first-level"> <a href="/about-us"> About Us</a> </li> <li> <a href="/about-us/leadership">Leadership</a> </li> <li> <a href="/about-us/our-promise">Our Promise</a> </li> <li> <a href="/about-us/policy-advocacy">Policy & Advocacy</a> </li> <li> <a href="/about-us/oncology">Our Focus on Oncology</a> </li> <li> <a href="/about-us/neuroscience">Our Focus on Neuroscience</a> </li> <li> <a href="/about-us/ophthalmology">Our Focus on Ophthalmology</a> </li> <li> <a href="/about-us/awards-recognition">Awards & Recognition</a> </li> <li> <a href="/about-us/investors">Investors</a> </li> <li> <a href="/about-us/suppliers">Suppliers</a> </li> <li> <a href="/about-us/california-transparency-law">CA Transparency in Supply </a> </li> <li> <a href="/about-us/compliance">Compliance Overview</a> </li> </ul> <ul> <li class="first-level"> <a href="/contact-us"> Contact Us</a> </li> <li> <a href="/contact-us/call-us">Call Us</a> </li> <li> <a href="/contact-us/email-us">Email Us</a> </li> <li> <a href="/contact-us/visit-us">Visit Us</a> </li> <li> <a href="/contact-us/submit-medical-inquiry">Submit a Medical Inquiry</a> </li> <li> <a href="/contact-us/submit-media-inquiry">Submit a Media Inquiry</a> </li> </ul> <ul> <li class="first-level"> <a href="/medical-professionals">For Medical Professionals</a> </li> <li> <a href="/medical-professionals/medicines">Our Medicines & Products</a> </li> <li> <a href="/medical-professionals/pipeline">Our Pipeline</a> </li> <li> <a href="/medical-professionals/medinfo">Medical Resources</a> </li> <li> <a href="/medical-professionals/clinical-trial-information">Clinical Trial Information</a> </li> <li> <a href="/medical-professionals/sunshine-act-compliance">Sunshine Act Compliance</a> </li> <li> <a href="/medical-professionals/product-security">Product Security</a> </li> </ul> <ul> <li class="first-level"> <a href="/partners">For Partners</a> </li> <li> <a href="/partners/our-approach">Our Approach</a> </li> <li> <a href="/partners/what-we-are-looking-for">What We Are Looking For</a> </li> <li> <a href="/partners/partner-with-us">Partner With Us</a> </li> <li> <a href="/partners/contacts">Contact Us</a> </li> <li> <a href="/partners/our-stories">Our Stories</a> </li> </ul> <ul> <li class="first-level"> <a href="/scientists">For Scientists</a> </li> <li> <a href="/scientists/our-scientists">Our Scientists</a> </li> <li> <a href="/scientists/our-pipeline">Our Pipeline</a> </li> <li> <a href="/scientists/behind-the-science">Our Stories</a> </li> <li> <a href="/scientists/our-podcast">Our Podcast</a> </li> <li> <a href="/scientists/publications">Publications</a> </li> <li> <a href="/scientists/mta">MTA Program</a> </li> </ul> <ul> <li class="first-level"> <a href="/media">For Media</a> </li> <li> <a href="/media/news-features">News Features</a> </li> <li> <a href="/media/press-releases">Press Releases</a> </li> <li> <a href="/media/statements">Statements</a> </li> <li> <a href="/media/company-information">Company Information</a> </li> <li> <a href="/media/news-alerts">Sign Up For News Alerts</a> </li> </ul> <ul> <li class="first-level"> <a href="/good">For Good</a> </li> <li> <a href="/good/giving">Giving</a> </li> <li> <a href="/good/diversity-inclusion">Diversity & Inclusion</a> </li> <li> <a href="/good/sustainability">Sustainability</a> </li> </ul> <ul> <li class="first-level"> <a href="/diversity-inclusion"> Inclusion & Belonging</a> </li> <li> <a href="/diversity-inclusion/advancing-inclusive-research">Advancing Inclusive Research</a> </li> <li> <a href="/diversity-inclusion/health-equity">Health Impact</a> </li> <li> <a href="/diversity-inclusion/transforming-society">Transforming Society</a> </li> </ul> <ul> <li class="first-level"> <a href="/careers">Now Hiring</a> </li> <li> <a href="/careers/find-a-job">Find A Job</a> </li> <li> <a href="/careers/professional-areas">Professional Areas</a> </li> </ul> <ul> <li class="first-level"> <a>—</a> </li> <li><button id="ot-sdk-btn" class="ot-sdk-show-settings">Your Privacy Choices</button></li> <li><a href="/privacy-policy">Privacy Policy</a></li> <li><a href="/wa-consumer-health-data-privacy-policy">WA Consumer Health Data Privacy Policy</a></li> <li><a href="/terms-conditions">Terms & Conditions</a></li> <li><a href="/accessibility">Accessibility</a></li> </ul> </nav> </div> <div class="constrained"> <div class="footer-social"> <div class="footer-social-list"> <a href="//facebook.com/genentech" target="_blank" data-service="facebook"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-facebook"></use> </svg> </a> <a href="//twitter.com/genentech" target="_blank" data-service="twitter"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-twitter"></use> </svg> </a> <a href="//linkedin.com/company/genentech" target="_blank" data-service="linkedin"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-linkedin"></use> </svg> </a> <a href="//youtube.com/genentech" target="_blank" data-service="youtube" style="padding: 5% 0%;"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-youtube"></use> </svg> </a> <a href="//pinterest.com/genentech" target="_blank" data-service="pinterest"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-pinterest"></use> </svg> </a> <a target="_blank" href="https://www.glassdoor.com/Overview/Working-at-Genentech-EI_IE274.11,20.htm" style="display: flex; align-items: center;"> <svg style="height: 22px;"> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-glassdoor" data-service="glassdoor"></use> </svg> </a> <a href="//instagram.com/genentech" target="_blank" data-service="instagram"> <svg> <use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-instagram"></use> </svg> </a> </div> </div> </div> <div class="constrained"> <div class="copyright">© 2025 Genentech, Inc. All rights reserved. This site is intended for US residents only.</div> </div> </div> <link rel="modulepreload" href="https://www.gene.com/build/assets/header-DyYXM6Vv.js" /><link rel="modulepreload" href="https://www.gene.com/build/assets/index-OaaOytLl.js" /><link rel="modulepreload" href="https://www.gene.com/build/assets/_commonjsHelpers-BosuxZz1.js" /><script type="module" src="https://www.gene.com/build/assets/header-DyYXM6Vv.js"></script> <script type="text/javascript" src="https://www.gene.com/assets/frontend/js/custom/galaxySearch.js"></script> <script src="/assets/frontend/js/vendor/jquery-1.7.2.min.js"></script> <script src="/assets/frontend/js/vendor/select2/dist/js/select2.full.min.js"></script> <script src="/assets/frontend/js/vendor/magnific-popup/dist/jquery.magnific-popup.min.js"></script> <script src="/assets/frontend/js/vendor/FitText.js/jquery.fittext.js"></script> <link rel="preload" as="style" href="https://www.gene.com/build/assets/main-site-DPpHmyQP.css" /><link rel="modulepreload" href="https://www.gene.com/build/assets/gene-scripts-f_I1C7nR.js" /><link rel="modulepreload" href="https://www.gene.com/build/assets/main-site-Cl_9bscq.js" /><link rel="modulepreload" href="https://www.gene.com/build/assets/_commonjsHelpers-BosuxZz1.js" /><link rel="modulepreload" href="https://www.gene.com/build/assets/base-component-o8ldAQHQ.js" /><link rel="modulepreload" href="https://www.gene.com/build/assets/window-events-B7aJfebw.js" /><link rel="modulepreload" href="https://www.gene.com/build/assets/product-select-Q4_aKJ6E.js" /><link rel="modulepreload" href="https://www.gene.com/build/assets/icons-loader-BY2iGxc9.js" /><link rel="stylesheet" href="https://www.gene.com/build/assets/main-site-DPpHmyQP.css" /><script type="module" src="https://www.gene.com/build/assets/gene-scripts-f_I1C7nR.js"></script><script type="module" src="https://www.gene.com/build/assets/main-site-Cl_9bscq.js"></script><script type="module" src="https://www.gene.com/build/assets/product-select-Q4_aKJ6E.js"></script><script type="module" src="https://www.gene.com/build/assets/icons-loader-BY2iGxc9.js"></script> <script src="/assets/frontend/js/custom/datatables.js"></script> <script> jQ.unq(); jQuery(function() { // Initialize custom classes for (var classname in Gene.custom) { if (classname != 'configs') { Gene.custom[classname].init(); } } }); </script> </body> </html>

CINXE.COM

Genentech: News Features